## 21.1116.02001

Sixty-seventh Legislative Assembly of North Dakota

## **HOUSE BILL NO. 1514**

Introduced by

Senators Clemens, O. Larsen, Luick

(Approved by the Delayed Bills Committee)

- 1 A BILL for an Act to create and enact a new section to chapter 23-16, a new section to chapter
- 2 43-15, and a new section to chapter 43-17 of the North Dakota Century Code, relating to a
- 3 hospital patient's right to try off-label use drugs, a hospital ban on discrimination based on
- 4 vaccinevaccination status, pharmacist fulfillment of off-label drug use prescriptions for the
- 5 treatment of COVID-19, and the board of medicine's authority to bring disciplinary actions; and
- 6 to provide an effective date.

## 7 BE IT ENACTED BY THE LEGISLATIVE ASSEMBLY OF NORTH DAKOTA:

- 8 **SECTION 1.** A new section to chapter 23-16 of the North Dakota Century Code is created 9 and enacted as follows:
- 10 Right to try off-label use drugs Ban on discrimination based on vaccinevaccination
  11 status.
- 12 <u>1. If a patient is prescribed a United States food and drug administration-approved drug</u>
  13 <u>for off-label use, a hospital shall honor that prescription.</u>
- SECTION 2. A new section to chapter 43-15 of the North Dakota Century Code is created and enacted as follows:
- 18 Off-label use COVID-19.
- 19 <u>If a pharmacist receives a United States food and drug administration-approved drug</u>
  20 <u>prescription for the off-label treatment or prevention of a disease or medical conditionsevere</u>
  21 <u>acute respiratory syndrome coronavirus 2 identified as SARS-CoV-2, or any mutation or viral</u>
- 22 | fragments of SARS-CoV-2, the pharmacist may not refuse to dispense the drug based on the
- 23 <u>pharmacist's professional judgment regarding the appropriateness of the prescription. This</u>

## Sixty-seventh Legislative Assembly

- 1 section does not prevent the pharmacist from contacting the prescriber regarding the
- 2 prescription.
- 3 SECTION 3. A new section to chapter 43-17 of the North Dakota Century Code is created
- 4 and enacted as follows:
- 5 <u>COVID-19 Limitations on disciplinary actions.</u>
- 6 The board may not take disciplinary action against a licensee based on the licensee
- 7 <u>distributing documented medical information, providing information regarding the licensee's</u>
- 8 professional experience or observations, or speaking against a public official. The board may
- 9 <u>not bring a disciplinary action against a licensee based on the prescription of a United States</u>
- 10 food and drug administration-approved drug for the off-label treatment or prevention of severe
- 11 <u>acute respiratory syndrome coronavirus 2 identified as SARS-CoV-2, or any mutation or viral</u>
- 12 <u>fragments of SARS-CoV-2.</u>
- 13 **SECTION 4. EFFECTIVE DATE.** This Act becomes effective upon its filing with the
- 14 secretary of state.